On July 12, 2024, U.S. Centers for Disease Control and Prevention (CDC) published updated webpages and guidance about working with specimens from patients suspected of having a viral hemorrhagic fever (VHF).

This guidance applies to VHFs caused by infections with filoviruses (orthoebolavirus and orthomarburgviruses), arenaviruses (Lassa, Lujo, Guanarito virus, Sabia virus, Junin virus, Chapare virus and Machupo virus), Rift Valley fever virus and Crimean Congo hemorrhagic fever virus. The guidance also applies to other high-consequence diseases, such as Nipah virus disease, that require a specialized laboratory, are highly pathogenic and have no vaccine or treatment currently available. For more information, please review these web pages in detail.